組換えタンパク質市場：製品別（成長因子、ケモカイン、構造タンパク質、膜タンパク質）、用途別（創薬・医薬品開発（生物製剤、ワクチン、細胞・遺伝子治療）、研究、バイオ医薬品生産）、地域別 - 2028年までの世界予測

Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028

組み換えタンパク質の世界市場規模は、2023年の22億米ドルから2028年には32億米ドルに達すると予測され、予測期間中の年平均成長率は7.2%である。特許切れによる生物製剤とバイオシミラーの需要増加、慢性疾患の... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2024年2月5日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	408	475	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

組み換えタンパク質の世界市場規模は、2023年の22億米ドルから2028年には32億米ドルに達すると予測され、予測期間中の年平均成長率は7.2%である。特許切れによる生物製剤とバイオシミラーの需要増加、慢性疾患の蔓延、ライフサイエンス研究開発に対する政府支援の増加、個別化医療への嗜好の高まりなどの要因である。
「組換えタンパク質市場では成長因子・ケモカインセグメントが圧倒的シェアを占める
製品別に見ると、世界の組み換えタンパク質市場は、成長因子とケモカイン、キナーゼタンパク質、膜タンパク質、免疫応答タンパク質、構造タンパク質、制御タンパク質、組み換え代謝酵素、接着分子と受容体、その他の組み換えタンパク質に区分される。成長因子とケモカインのセグメントはさらにインターフェロン、インターロイキン、その他の成長因子とケモカインにセグメント化される。成長因子およびケモカインセグメントは、細胞培養、タンパク質発現、細胞反応の調節への応用により、著しいCAGRで成長すると予想される。

"2022年、創薬・開発分野がアプリケーション分野で最大のシェアを占める"
用途別では、組換えタンパク質市場は、創薬・開発、バイオ医薬品生産、研究、診断、その他の用途に区分される。2022年には、創薬・開発分野が組換えタンパク質市場で最大のシェアを占めた。同セグメントは、バイオ医薬品の開発や潜在的な創薬ターゲットの機能解明における組み換えタンパク質の応用により、市場で最大のシェアを占めている。

「アジア太平洋地域は組換えタンパク質市場でより速いペースで成長する可能性が高い。
組換えタンパク質市場の地域は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカに区分される。アジア太平洋地域は、予測期間中に大きなCAGRで成長すると予想されている。同地域の成長の主な原動力は、タンパク質ベースの医薬品に対する需要の増加、組換えタンパク質生産に対する政府資金の増加、バイオテクノロジーベースの医薬品開発である。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 回答者の役職別（供給側）マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米：40％、欧州：25％、アジア太平洋地域：20％、中南米：10％、中東・アフリカ：5
レポート掲載企業一覧
- バイオテクネ社（米国）
- サーモフィッシャーサイエンティフィック（米国）
- メルクKGaA（ドイツ）
- アブカム社（英国）
- アブノバ・コーポレーション（台湾）
- バイオレジェンド（米国）
- バイオ・ラッド・ラボラトリーズ（米）
- BPSバイオサイエンス（米国）
- エンゾ・バイオケム（米国）
- ジェンスクリプト（中国）
- Miltenyi Biotec B.V. & Co.KG（ドイツ）
- プロテインテック・グループ（米国）
- シノバイオ（中国）
- アクロバイオシステムズグループ（米国）
- アビバ・システム・バイオロジー・コーポレーション（米国）
- ザルトリウス・セルジェニックス社（ドイツ）
- イコサゲン（エストニア）
- ニューロミクス（米）
- プロスペック・タニー・テクノジーン社（イスラエル(イスラエル）
- プロテオジェニクス社（フランス）
- レイバイオテック（米国）
- ラウラウス・バイオ（インド）
- ステムセル・テクノロジーズ（カナダ）
- ストレスマルク・バイオサイエンシズ（カナダ）
- ユナイテッド・ステーツ・バイオロジカル（米国）

調査範囲
この調査レポートは組換えタンパク質市場の詳細な姿を提供しています。製品、用途、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主な利点
本レポートは、組換えタンパク質市場全体とそのサブセグメントについて、最も近似した収益数値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主要な促進要因（慢性疾患の罹患率の上昇、特許満了に伴う生物製剤とバイオシミラーの技術革新の解放、ライフサイエンス分野の研究開発に対する政府支援の増加、個別化医療への嗜好の高まり）、阻害要因（高い生産コスト、厳しい規制当局の承認プロセス）、機会（遺伝子編集技術の進歩、新興市場の高い成長可能性、新規発現システムの出現）、課題（送達システムに関連する課題）の分析が組換えタンパク質市場の成長に影響を与えている。
- 製品開発/イノベーション：組換えタンパク質市場の新規上市製品に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、様々な地域にわたる組み換えタンパク質市場を分析しています。
- 市場の多様化：リコンビナントタンパク質市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競争力の評価：Bio-Techne社（米国）、Thermo Fisher Scientific社（米国）、Merck KGaA社（ドイツ）、Abcam plc社（英国）、Abnova Corporation社（台湾）、Biolegend Inc社（米国）、Bio-Rad Laboratories社（米国）、BPS Bioscienc Inc社（米国）、Enzo Biochem Inc社（米国）、GenScript社（中国）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 35
1.3.3 CURRENCY CONSIDERED 35
1.4 RESEARCH LIMITATIONS 35
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 36
1.7 RECESSION IMPACT 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
FIGURE 1 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES 40
2.2 MARKET SIZE ESTIMATION 41
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022) 41
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 42
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022) 42
2.2.1 INSIGHTS FROM PRIMARIES 44
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 44
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER) 44
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44
2.3 GROWTH RATE ASSUMPTIONS 45
FIGURE 8 RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023–2028) 46
FIGURE 9 RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 46
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
2.5 STUDY ASSUMPTIONS 48
2.6 RISK ANALYSIS 48
2.7 RECESSION IMPACT ANALYSIS 48
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024−2028 (% GROWTH) 49
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 49
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 49
3 EXECUTIVE SUMMARY 50
FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 50
FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION) 53
FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 54
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET 55
4 PREMIUM INSIGHTS 56
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 56
FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET 56
4.2 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022) 57
FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 57
4.3 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 58
FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 60
5.2.1.1 Rising incidence of chronic diseases 60
FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022) 61
5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry 62
5.2.1.3 Increasing government support for R&D in life sciences 63
TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022) 63
5.2.1.4 Growing preference for personalized medicine 64
5.2.2 RESTRAINTS 64
5.2.2.1 High production costs 64
5.2.2.2 Stringent regulatory approval processes 65
5.2.3 OPPORTUNITIES 66
5.2.3.1 Advancements in gene editing technologies 66
5.2.3.2 High growth potential of emerging markets 67
5.2.3.3 Emergence of novel expression systems 68
5.2.4 CHALLENGES 69
5.2.4.1 Challenges associated with delivery systems 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS 69
5.4 PRICING ANALYSIS 70
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 70
TABLE 6 RECOMBINANT PROTEIN PRODUCTS 70
5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS 74
5.5 TECHNOLOGY ANALYSIS 74
5.6 VALUE CHAIN ANALYSIS 75
FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS 76
5.7 ECOSYSTEM MARKET/MAP 77
FIGURE 26 ECOSYSTEM MARKET/MAP 77
TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM: 77
5.8 REGULATORY ANALYSIS 79
TABLE 8 KEY REGULATORY AGENCIES 79
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
5.9 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.9.1 THREAT OF NEW ENTRANTS 85
5.9.2 THREAT OF SUBSTITUTES 85
5.9.3 BARGAINING POWER OF SUPPLIERS 86
5.9.4 BARGAINING POWER OF BUYERS 86
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.10 PATENT ANALYSIS 87
FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013–DECEMBER 2023 87
TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS 87
5.11 KEY CONFERENCES AND EVENTS 89
TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023–2024) 89
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 90
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS 90
5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS 91
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 91
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 92
6.1 INTRODUCTION 93
TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93
6.2 GROWTH FACTORS & CHEMOKINES 93
TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 95
TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021–2028 (USD MILLION) 98
6.2.1 INTERFERONS (IFNS) 98
6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market 98
TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 102
6.2.2 INTERLEUKINS (ILS) 102
6.2.2.1 Rising focus on personalized therapeutics to drive market 102
TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 35 ASAI PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.2.3 OTHER GROWTH FACTORS & CHEMOKINES 105
TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.3 IMMUNE RESPONSE PROTEINS 109
6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET 109
TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.4 STRUCTURAL PROTEINS 112
6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET 112
TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.5 MEMBRANE PROTEINS 116
6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH 116
TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.6 KINASE PROTEINS 119
6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET 119
TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 122
6.7 REGULATORY PROTEINS 122
6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET 122
TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.8 RECOMBINANT METABOLIC ENZYMES 126
6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND 126
TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.9 ADHESION MOLECULES & RECEPTORS 129
6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH 129
TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 132
6.10 OTHER RECOMBINANT PROTEINS 132
TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 135

7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 136
7.1 INTRODUCTION 137
TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
7.2 DRUG DISCOVERY & DEVELOPMENT 137
TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
7.2.1 BIOLOGICS 141
7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market 141
TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS 141
TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 144
7.2.2 VACCINES 144
7.2.2.1 Rising incidence of infectious diseases to boost demand 144
TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 145
TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 147
7.2.3 CELL & GENE THERAPY 147
7.2.3.1 Growing focus on CAR-T therapies to propel market 147
TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 148
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 151
7.3 RESEARCH 151
TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021–2028 USD MILLION) 152
TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 154
7.3.1 ACADEMIC RESEARCH 154
7.3.1.1 Wide application in molecular & gene expression studies to propel market 154
TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 129 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 130 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 131 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 157
7.3.2 BIOTECHNOLOGY RESEARCH 157
7.3.2.1 Growing focus on bioengineering and genomics to fuel market 157
TABLE 132 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 133 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 134 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 135 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 136 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 137 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 161
7.4 BIOPHARMACEUTICAL PRODUCTION 161
7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH 161
TABLE 138 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 139 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 140 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 141 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 142 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 143 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 164
7.5 DIAGNOSTICS 164
7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET 164
TABLE 144 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 145 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 146 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 147 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 148 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 149 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 167
7.6 OTHER APPLICATIONS 167
TABLE 150 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 168
TABLE 151 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 152 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 154 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 155 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
8 RECOMBINANT PROTEINS MARKET, BY HOST CELL 171
8.1 INTRODUCTION 172
TABLE 156 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 172
8.2 MAMMALIAN SYSTEMS 172
8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET 172
TABLE 157 RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 158 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 159 EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 160 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 161 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 162 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 175
8.3 INSECT CELLS 175
8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET 175
TABLE 163 RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021–2028 (USD MILLION) 176
TABLE 164 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 165 EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 166 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 167 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 168 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 179
8.4 YEAST & FUNGI 179
8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND 179
TABLE 169 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021–2028 (USD MILLION) 180
TABLE 170 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 171 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 172 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 173 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 174 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 182
8.5 BACTERIAL CELLS 182
8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET 182
TABLE 175 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 176 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 177 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 178 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 179 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 180 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
8.6 OTHER HOST CELLS 186
TABLE 181 RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021–2028 (USD MILLION) 186
TABLE 182 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 183 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 184 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 185 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 186 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 189
9 RECOMBINANT PROTEINS MARKET, BY END USER 190
9.1 INTRODUCTION 191
TABLE 187 RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 191
9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET 191
TABLE 188 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 193
TABLE 189 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 190 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 191 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 192 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 193 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
9.3 BIOTECHNOLOGY COMPANIES 195
9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND 195
TABLE 194 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 196
TABLE 195 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 196
TABLE 196 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 197 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 198 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 199 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 198
9.4 ACADEMIC & RESEARCH INSTITUTES 199
9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET 199
TABLE 200 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 200
TABLE 201 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 200
TABLE 202 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 203 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 204 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 202
9.5 CONTRACT RESEARCH ORGANIZATIONS 202
9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH 202
TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION) 203
TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 205
9.6 OTHER END USERS 205
TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 206
TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 USD MILLION) 208
TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 208

ページTOPに戻る

Table of Contents

Summary

The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period. Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..
“The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market”
Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.

“Drug discovery & development segment accounted for the largest share of the application segment in 2022.”
Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.

“Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market.”
The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%
List of Companies Profiled in the Report:
• Bio-Techne (US)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Abcam plc (UK)
• Abnova Corporation (Taiwan)
• Biolegend Inc (US)
• Bio-Rad Laboratories Inc. (US)
• BPS Bioscienc Inc (US)
• Enzo Biochem, Inc. (US)
• GenScript (China)
• Miltenyi Biotec B.V. & Co. KG (Germany)
• Proteintech Group, Inc. (US)
• Sino Biological Inc. (China)
• ACROBiosystems Group (US)
• Aviva Systems Biology Corporation (US)
• Sartorius CellGenix GmbH (Germany)
• Icosagen (Estonia)
• Neuromics (US)
• ProSpec-Tany Technogene Ltd. (Israel)
• ProteoGenix S.A.S (France)
• RayBiotech Inc (US)
• Lauraus Bio (India)
• Stemcell Technologies (Canada)
• StressMarq Biosciences Inc. (Canada)
• United States Biological (US)

Research Coverage:
This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.
• Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the recombinant proteins market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biolegend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?